Eli Lilly maintains competitiveness by balancing immediate execution on successful franchises like GLP-1 drugs while investing in a diverse portfolio of long-term scientific opportunities.

“I think we have an obligation to our newest employee just joined to have a business by the time they get to a senior level and we certainly have a role in the world at changing human health so we are investing pretty broadly in cancer and Immunology maybe in brain disease”